Quiet Therapeutics

Anticancer Therapeutics Using Nanoparticles and Biomarkers

Health Tech & Life Sciences
Non Active, Feb 2017
Series A Ness Ziona Founded 2010
Total raised
$18.5M
Last: Series A 2015-04
Stage
Series A
Founded
2010
Headcount
6
HQ
Ness Ziona
Sector
Health Tech & Life Sciences

About

Quiet Therapeutics is a cancer drug discovery and development company that is creating a new generation of cancer therapeutics utilizing its proprietary GAGomer technology to specifically target tumor cells. The GAGomer therapeutic nanoparticles have the ability to target certain types of cancers that express a biomarker. Once the nanoparticles target the specific cancer cells, they deliver a therapeutic payload that leads to the death of the cancer cells. This new class of cancer treatment enables the flexibility of delivering a medicine that can kill the cancer cells, block the production of proteins that promote the cancer, or even use the cancer cells own machinery to produce proteins that kill the cancer cells. Quiet Therapeutics develops a diverse set of DNA, RNA, and small molecule anticancer therapeutics.

Funding history · 2 rounds · $18.5M total

2015-04
Series A $12.0M
2013-01
Seed $5.5M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

oncologybiotechnologybiomarkerspharmaceuticalsmedical-technologiesnanotechnologytherapeuticsdrug-deliveryinflammatory-diseasespharma-companiestargeted-therapycancer